Hu v. Janssen Pharmaceuticals, Inc.

Court of Appeals for the Ninth Circuit·Decided May 20, 2026·No. 24-6300·Unpublished

Opinion

NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS MAY 20 2026 MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS FOR THE NINTH CIRCUIT

SOPHIE HU; FUMIAN ZHAO, No. 24-6300 D.C. No. Plaintiffs - Appellants, 4:21-cv-05990-HSG v. MEMORANDUM* JANSSEN PHARMACEUTICALS, INC.; BAYER HEALTHCARE PHARMACEUTICALS INC.,

Defendants - Appellees.

Appeal from the United States District Court for the Northern District of California Haywood S. Gilliam, Jr., District Judge, Presiding

Submitted March 31, 2026**

Before: NGUYEN, MILLER, and COLLINS, Circuit Judges. Plaintiff-Appellant Sophie Hu (“Hu”) brought this action against

Defendants-Appellees Janssen Pharmaceuticals, Inc. and Bayer Healthcare

Pharmaceuticals, Inc. (collectively, “Defendants”) on behalf of herself and her

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. ** The panel unanimously concludes this case is suitable for decision without oral argument. See Fed. R. App. P. 34(a)(2). mother, Fumian Zhao, alleging that her mother became incapacitated after taking

the medication Xarelto. The district court granted Defendants’ motion to dismiss

Hu’s loss of consortium claim with prejudice, and her remaining claims without

prejudice. We have jurisdiction under 28 U.S.C. § 1291, and we affirm.

We review de novo a grant of a motion to dismiss. Simon v. Hartford Life,

Inc., 546 F.3d 661, 663–64 (9th Cir. 2008). Likewise, we review questions of

standing de novo. Johns v. Cnty. of San Diego, 114 F.3d 874, 876 (9th Cir. 1997).

1. The district court did not err in dismissing Hu’s loss of consortium

cause of action because, under California law, a child cannot bring a nonstatutory

claim for loss of parental consortium. See Borer v. Am. Airlines, Inc., 19 Cal. 3d

441, 444, 453 (1977); see also Tullai v. Homan, 195 Cal. App. 3d 1184, 1186

(1987).

2. Further, while we are sympathetic to Hu’s inability to find an

attorney, a conservator or guardian ad litem does not have standing to prosecute an

action pro se on another’s behalf. Simon, 546 F.3d at 664 (“It is well established

that the privilege to represent oneself pro se provided by [28 U.S.C.] § 1654 is

personal to the litigant and does not extend to other parties or entities.”); see Johns,

114 F.3d at 876–77 (holding that a parent or guardian cannot bring an action on

behalf of a child or incompetent person without retaining a lawyer); see also C.E.

Pope Equity Tr. v. United States, 818 F.2d 696, 697 (9th Cir. 1987) (“Although a

2 24-6300 non-attorney may appear in propria persona in his own behalf, that privilege is

personal to him.”). Because Hu is not an attorney, and is not represented by

counsel, the district court did not err in dismissing the remaining causes of action

without prejudice.

AFFIRMED.

3 24-6300

Free access — add to your briefcase to read the full text and ask questions with AI

Hu v. Janssen Pharmaceuticals, Inc., (9th Cir. 2026).

Hu v. Janssen Pharmaceuticals, Inc. (Hu v. Janssen Pharmaceuticals, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Borer v. American Airlines, Inc.
563 P.2d 858 (California Supreme Court, 1977)
Simon v. Hartford Life, Inc.
546 F.3d 661 (Ninth Circuit, 2008)
Tullai v. Homan
195 Cal. App. 3d 1184 (California Court of Appeal, 1987)